Hal Bar­ron’s swan song as GSK R&D chief ends with a promise: The best is yet to come

Em­ma Walm­s­ley has one cen­tral mes­sage for to­day’s Q4 up­date: Start­ing in 2022, Glax­o­SmithK­line will be­gin a new era of growth.

The long-an­tic­i­pat­ed spin­off of its con­sumer health­care joint ven­ture — with its nu­mer­ous twists and turns, in­clud­ing a re­cent re­jec­tion of Unilever’s bid to buy it out in­stead — is ex­pect­ed to be com­plet­ed some time this sum­mer. That puts the em­pha­sis en­tire­ly on in­no­va­tion at the phar­ma gi­ant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER